dr reddy’s laboratories limited 2003
TRANSCRIPT
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
1/14
DR REDDY S LABORATORIESLTD
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
2/14
COMPANY BACKGROUND
Dr.Reddy s Laboratories Ltd founded in 1984 byDr k.Angi Reddy has become India s second
biggest pharmaceutical company and itsheadquartered is in Hyderabad.It produces and sells active pharmaceuticalingredients , finished dosages and biologics.
It manufactures ulcer medicines, antibiotics, painrelievers, antidepressants and cardiovasculardrugs.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
3/14
COMPANY BACKGROUND
Dr Reddy s market its product in approximately100 countries , focusing on Europe,India,US and
Russia.The company employed over 8255 personnel,In 1997 it became the first Indian company toout-license an original molecule (DRF 2593).
Its revenue for 2006 - 2007 amounted to $ 1.5billion, an increase of 24.3% of the previous year. Its net income amounts to $ 216 million.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
4/14
COMPANY BACKGROUND
ON 11 April 2001, Dr Reddy s became the firstpharmaceutical company from Asia Pacific to be
listed onN
ewyork stock exchange.The company carries out research anddevelopment in diabetes, cancer, cardiovasculardiseases and bacterial infections.
The company has over 120 medications and 60active pharmaceutical ingredients for drugmanufacture .
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
5/14
Key personnel
C hairman: Dr. K.AngiReddy
C EO : G V Prasad
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
6/14
Dr Reddy s laboratories in
European unionIn 2006 2007, Dr Reddy s generated a revenueof EUR 80.5 million from Europe , which
accounted for 18% of the company s totalrevenue.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
7/14
Dr Reddy s Laboratories in
GermanyIn march 2006 Dr.reddy s acquired Betapharm
arzneimittel GmbH from 3i for euro 480 million.
Betapharm employs more than 350 personneland its turnover amounts to Euro 186 million . Itcommands a share of 3.5 % in the Germanpharmaceutical market.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
8/14
Dr.Reddy Laboratory in UK
In March 2002 Dr Reddy s acquired BHMLaboratories ,Beverley, and its wholly ownedsubsidiary meridian health care, EUR O 14.81million. Recently Dr. Reddy s entered into R & Dand C ommercialization agreement with ArgentaDiscovery Ltd, for the treatment of C O PD
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
9/14
In other European countries
Apart from subsidiaries in Germany and UK ,Dr.Reddy s has agreements in followingEuropean countries.
DEN MARKIRELAN DN ETHERLAN DS
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
10/14
F actors for success
C ontrolling the entire value chainImplementations of efficient new product
development processesHigh standard of corporate governance
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
11/14
Controlling the entire value
chainDr.Reddy s controls the entire supply chain and
offers high quality products at competitive pricesat opportune time . In addition it ensures thatquality is maintained at every stage.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
12/14
Imple
mentations of efficient newproduct develop ment processes
Targeting the streamlining of new productdevelopment process, Dr. Reddy s implemented
project racha using Microsoft accelerator for sixsigma. This is helping the company in taking keydecisions to launch the right products in themarket at the appropriate time.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
13/14
High standard of corporate
governanceDr.Reddy s adherence to high standard of
corporate governance and ethical businesspractices has been a key factor to its success. Themutual trust has ensured greater success for thecompany.
-
8/8/2019 DR REDDYS LABORATORIES LIMITED 2003
14/14
F uture plans
Having acquired Betapharm, one of thefastest growing generic companies in Germanyover the past 5 years, Dr.Reddy s aims atleveraging this strategic investment to evolveinto a mid-sized global pharmaceutical company.Dr.Reddy s aims to increase its revenue
substantially and improve its operating margin.